

1 **This paper is a preprint submitted to SportRxiv**

2

3 **Cite as: Dean, E., Osborne, A., Subar, D., Hendrickse, P., and Gaffney, C.J.**
4 ***(2025) Comparative effects of a glucose-fructose bar, glucose-fructose***
5 ***hydrogel, and a maltodextrin gel on carbohydrate oxidation and sprint***
6 ***performance in tier two athletes.***

7

8 **Title**

9 *Comparative Effects of a Glucose-Fructose bar, Glucose-Fructose hydrogel, and a*
10 *Maltodextrin gel on Carbohydrate Oxidation and Sprint Performance in Tier two*
11 *Athletes*

12

13

14 Ewan Dean¹, Ash Osborne¹, Paul Hendrickse¹, Daren Subar^{1,2}, & Christopher J.
15 Gaffney¹

16

17 1 – Lancaster University Medical School, Lancaster University, Lancaster,
18 Lancashire, UK

19 2 – BRIDGES Research Group, Department of Surgery, East Lancashire Hospitals
20 NHS Trust, Blackburn, Lancashire, UK East Lancashire Hospitals NHS Trust,
21 Blackburn, Lancashire, UK

22 Corresponding author – Ewan Dean. Email: e.dean1@lancaster.ac.uk. Lancaster
23 University Medical School, Lancaster University, Lancaster, Lancashire, UK

24

25

26 **Abstract**

27 Carbohydrate supplementation plays a key role in optimising athletic performance.
28 We compared the efficacy of three commercial carbohydrate supplements: a
29 glucose-fructose bar (VOOM), a fructose-glucose hydrogel (MAU), and a
30 maltodextrin-based gel (SIS). Antegrade venous blood samples for glucose and
31 insulin were measured alongside substrate utilisation in healthy Tier 2 athletes after
32 ingesting 45 g of carbohydrates from VOOM, MAU, and SIS during a modified 1-hour
33 Oral Glucose Tolerance Test (OGTT). Additionally, the effect of supplementation on
34 high-intensity interval exercise was evaluated during repeat maximal sprint
35 performance. During the OGTT, VOOM elicited greater total carbohydrate oxidation
36 than SIS (24.6 ± 7.4 g vs 17.8 ± 8.6 g, $p = 0.03$) but not MAU (20.1 ± 6.4 g, $p >$
37 0.05). Carbohydrate oxidation per minute varied over time ($p < 0.0001$) and between
38 products ($p = 0.04$), with VOOM (0.27 ± 0.05 g·min⁻¹) showing higher oxidation than
39 MAU (0.21 ± 0.05 g·min⁻¹) and SIS (0.19 ± 0.06 g·min⁻¹). No significant differences
40 were observed in glucose peak, time to peak glucose, or total insulin concentration
41 ($p > 0.05$). In the exercise trial, peak power ($p < 0.01$), mean power ($p < 0.0001$), and
42 total work varied across subsequent sprints ($p < 0.0001$) but were not influenced by
43 product ($p > 0.05$). Perceived exertion and gastrointestinal discomfort were similar
44 between products ($p > 0.05$). Despite differences in carbohydrate oxidation during
45 the OGTT, VOOM, MAU, and SIS displayed similar metabolic and sprint
46 performance outcomes, suggesting that, within this study, carbohydrate formulation
47 did not impact short-duration maximal exercise.

48

49 **Keywords**

50 Carbohydrates ; Supplements ; Exercise ; Oxidation ; Glucose

51

52 **Introduction**

53 Carbohydrate supplementation during exercise has well-documented effects
54 including enhancing performance, oxidation, and delaying fatigue (Podlogar & Wallis,
55 2022). This is achieved by providing rapid energy availability in the form of
56 convenient supplements, like gels, drinks, and bars, typically composed of easily
57 digestible monosaccharides (e.g., glucose and fructose), disaccharides (e.g.,
58 sucrose), and specific high glycaemic index polysaccharides (e.g., maltodextrin)
59 (Gromova et al., 2021; Rollo et al., 2020).

60

61 Different carbohydrate supplements utilise a variety of compositions, such as
62 glucose-fructose mixtures. This variety can be overwhelming for consumers,
63 particularly as carbohydrate intake should be tailored to exercise duration, intensity,
64 and individual preference (Jeukendrup, 2014; Podlogar & Wallis, 2022). Gels offer
65 fast, easily digestible carbohydrates and, although previously linked to
66 gastrointestinal discomfort (Saunders et al., 2007; Pfeiffer et al., 2010), recent
67 formulations of glucose-fructose mixtures are now shown to be well tolerated even at
68 high carbohydrate intake levels of $120 \text{ g}\cdot\text{h}^{-1}$ (Hearris et al., 2022). Drinks provide
69 hydration alongside carbohydrates and electrolytes and are again shown to be well
70 tolerated at up to $120 \text{ g}\cdot\text{h}^{-1}$ (Hearris et al., 2022; Podlogar et al., 2022). Bars, while
71 nutritionally comparable, may be less convenient due to their solid form and potential
72 to cause gastrointestinal discomfort during exercise (Guillochon & Rowlands., 2017).
73 Despite these subtle differences, research indicates similar performance outcomes
74 across all three. Pfeiffer et al. (2010) demonstrated the consumption of a solid
75 glucose-fructose bar elicited similar peak carbohydrate oxidation rates to a glucose-

76 fructose drink during 180 minutes of cycling (Bar $1.25 \pm 0.15 \text{ g}\cdot\text{min}^{-1}$ and Drink 1.34
77 $\pm 0.27 \text{ g}\cdot\text{min}^{-1}$). Similarly, Hearn et al. (2022) demonstrated comparable high rates
78 of carbohydrate oxidation from solid (jelly chew), semisolid (gel), fluid (drink), and a
79 combination of the forms (mix) during 180 minutes of cycling and an exercise
80 capacity test. Peak carbohydrate oxidation was similar across all three forms (Chew
81 $1.59 \pm 0.08 \text{ g}\cdot\text{min}^{-1}$, Gel $1.58 \pm 0.13 \text{ g}\cdot\text{min}^{-1}$, Drink $1.56 \pm 0.16 \text{ g}\cdot\text{min}^{-1}$, Mix
82 $1.66 \pm 0.02 \text{ g}\cdot\text{min}^{-1}$).

83

84 The carbohydrate composition of energy products is typically formulated to maximise
85 the absorption of sugars into the bloodstream, where they can be utilised as an
86 immediate source of energy. Historically, carbohydrate oxidation during exercise was
87 thought to be limited to approximately $60 \text{ g}\cdot\text{h}^{-1}$, based on the assumption that the
88 intestinal glucose transporters became saturated beyond this threshold (Jeukendrup
89 & Jentjens, 2000). However, subsequent research has shown that combining
90 different carbohydrate types – such as glucose and fructose – can enhance
91 absorption via distinct intestinal transporters: sodium-glucose transporter 1 (SGLT1)
92 for glucose and glucose transporter 5 (GLUT5) for fructose (Jentjens et al., 2004;
93 Jeukendrup, 2010). This strategy, including combinations like maltodextrin and
94 fructose, has been shown to significantly increase carbohydrate oxidation rates. For
95 example, Wallis et al. (2005) demonstrated that ingestion of maltodextrin and
96 fructose at $1.8 \text{ g}\cdot\text{min}^{-1}$ ($\sim 108 \text{ g}\cdot\text{h}^{-1}$) resulted in a higher peak exogenous
97 carbohydrate oxidation rate compared to maltodextrin alone (1.50 ± 0.07 vs. $1.06 \pm$
98 $0.08 \text{ g}\cdot\text{min}^{-1}$). Similarly, Podlogar et al. (2022) reported greater oxidation rates when
99 carbohydrates were consumed at $120 \text{ g}\cdot\text{h}^{-1}$ in a 0.8:1 fructose-to-glucose ratio
100 compared to $90 \text{ g}\cdot\text{h}^{-1}$ in a 1:2 ratio (1.51 ± 0.22 vs. $1.29 \pm 0.60 \text{ g}\cdot\text{min}^{-1}$).

101 Furthermore, Hearnis et al. (2022) found that ingesting glucose-fructose at $120 \text{ g}\cdot\text{h}^{-1}$
102 improved exercise capacity across four different feeding formats; drink ($446 \pm 350 \text{ s}$),
103 gel ($529 \pm 396 \text{ s}$), chew ($596 \pm 416 \text{ s}$), and mixed format ($470 \pm 395 \text{ s}$) compared to
104 water ($231 \pm 244 \text{ s}$), during 180 minutes cycling at 95% lactate threshold followed by
105 an exercise capacity test at 150% lactate threshold.

106

107 While mainly associated with endurance performance, carbohydrate
108 supplementation may also support high-intensity exercise. Vigh-Larsen et al. (2024)
109 demonstrated carbohydrate ingestion during repeated high-intensity exercise-
110 maintained blood glucose (5.3 ± 0.2 vs $4.1 \pm 0.2 \text{ mmol/L}$) and reported a fivefold
111 greater increase in plasma insulin with carbohydrate ingestion compared to a
112 placebo. The authors suggest carbohydrate ingestion during high-intensity exercise
113 may create a greater reliance on carbohydrate oxidation and possibly preserve liver
114 glycogen. This may help to prevent hypoglycaemia and delay fatigue. Rodriguez-
115 Giustiniani et al. (2019) observed a 13% improvement in high-intensity running
116 capacity in football players, with higher glucose levels at halftime (5.8 ± 0.5 vs.
117 $4.1 \pm 0.4 \text{ mmol/L}$) and post-exercise (4.9 ± 0.4 vs. $4.3 \pm 0.4 \text{ mmol/L}$). Krings et al.
118 (2017) similarly demonstrated performance benefits during repeated maximal cycling
119 sprints, with higher mean power output (659.3 ± 103.0 vs. $645.8 \pm 99.7 \text{ watts}$), total
120 work (9849.8 ± 1598.8 vs. $9447.5 \pm 1684.9 \text{ joules}$), and a lower fatigue index
121 (15.3 ± 8.6 vs. $17.7 \pm 10.4 \text{ watts/s}$) following carbohydrate ingestion.

122

123 While research on carbohydrate supplementation has established important
124 nutritional strategies, such as carbohydrate loading (Baker et al., 2015; Ismardi et al.,
125 2024; Kazemi et al., 2023), there remains limited evidence evaluating the efficacy of

126 different commercially available carbohydrate supplements. This research can help
127 athletes make informed decisions of the effectiveness of their nutritional
128 supplements. The present study aimed to compare the postprandial glucose
129 responses between three commercially available carbohydrate supplements at rest
130 and during high-intensity exercise, in addition to their effects on high-intensity
131 exercise performance. The commercially available carbohydrate supplements
132 compared in this study were the glucose-fructose Voom Pocket Rocket Electro
133 Energy bar (VOOM), the fructose-glucose hydrogel Maurten Gel 160 (MAU), and the
134 maltodextrin-based Science in Sport Go Isotonic Energy gel (SIS).

135

136 **Materials and methods**

137 **Subjects**

138 All subjects were classified as Tier 2 athletes, as defined by McKay et al. (2022),
139 indicating they trained regularly (~3 times per week) with the purpose of competing in
140 their respective sports, including running, cycling, or triathlon.

141

142 The modified oral glucose tolerance trial (OGTT) aimed to assess metabolic
143 responses (glucose, insulin, substrate oxidation), which are known to vary by sex
144 due to hormonal fluctuations, particularly in females during different phases of the
145 menstrual cycle (Ciarambino et al., 2023; Tucker et al., 2025). To reduce
146 heterogeneity and improve internal validity, only males were recruited.

147

148 In contrast, the exercise trial focussed on exercise performance in a mixed-sex
149 athletic population. Given the applied nature of this protocol and the emphasis on
150 ecological validity, both male and female athletes were included to better reflect real-

151 world sporting contexts. Appropriate standardisation procedures (time of day, pre-
 152 trial nutrition, and self-reported menstrual cycle phase) were implemented to
 153 minimise heterogeneity (Elliot-Sale et al., 2020; Smeith et al., 2024).

154

155 Table 1. Anthropometric characteristics

Subjects	OGTT (16 males)	Exercise (5 males)	Exercise (5 females)	Exercise (total)
Age (y)	23 ± 4.2	27.8 ± 5.7	23.2 ± 1.8	25.5 ± 4.7
Height (cm)	182.0 ± 6.5	181.9 ± 3.4	170.7 ± 6.2	176.3 ± 7.6
Weight (kg)	79.5 ± 8.3	80.4 ± 7.8	68.1 ± 8.9	74.3 ± 10.3
BMI (kg/m ²)	23.81 ± 1.2	23.8 ± 1.3	22.7 ± 2.1	23.2 ± 10.3
Lean mass (kg)	65.8 ± 5.4	65.6 ± 3.9	48.3 ± 3.1	56.9 ± 9.7
Body fat (%)	14.5 ± 5.0	13.7 ± 3.5	24.6 ± 5.7	19.2 ± 7.3

156 Values are means ± SD. OGTT = Oral glucose tolerance test. BMI = Body mass
 157 index

158

159 **Oral glucose tolerance test (OGTT)**

160 For the OGTT trial, sixteen healthy male Tier 2 athletes (mean ± standard deviation,
 161 SD) (aged 23 ± 4.2 years; height 182.0 ± 6.5 cm; weight 79.5 ± 8.3 kg; BMI 23.8 ±
 162 1.2 kg/m²) were recruited. For the exercise trial, ten healthy male and female Tier 2
 163 athletes (aged 25 ± 4.7 years; height 176.3 ± 7.6 cm; weight 74.3 ± 10.3 kg; BMI
 164 23.2 ± 10.3 kg/m²) were recruited. In both studies, participants were fully informed of
 165 all procedures and potential risks before providing written informed consent. All
 166 protocols were approved by the Lancaster University Ethics Committee and
 167 conducted in accordance with the *Declaration of Helsinki (8th Revision, World*

168 Medical Association, 2025) and Good Clinical Practice. Both studies used a
169 randomised crossover design and were preregistered on clinicaltrials.gov: OGTT trial
170 (NCT06375577) and Exercise trial (NCT06768333).

171

172 **Medical screening**

173 All subjects completed a medical screening form aligned with the American College
174 of Sports Medicine (ACSM) safety-to-exercise guidelines (Liguori, 2020) to confirm
175 no contraindications to exercise or allergies to the carbohydrate products, as
176 previously described in our lab (Gaffney et al., 2022). Subjects were excluded if they
177 had any diagnosed medical condition, took prescribed medication, or adhered to
178 diets (such as high carbohydrate-low fat, or low carbohydrate-high fat) affecting gut
179 microbiome glucose responses (Rauch et al., 2022). Height and body mass were
180 measured using an ultrasonic stadiometer and scales (217 ultrasonic stadiometer
181 and scales, Seca, Hamburg, Germany), while body composition was assessed with
182 bioimpedance scales (DC-430P, Tanita, Tokyo, Japan). Blood pressure was
183 measured using an automatic blood pressure monitor (M3 Comfort, Omron, Kyoto,
184 Japan) to ensure subjects were safe to exercise.

185

186 **Experimental protocols**

187 Both the OGTT and exercise study were conducted following a double-blind
188 randomised crossover design and required three experimental visits each, separated
189 by a minimum of 48 hours to replicate the frequency of Tier 2 athletes' training.

190

191 **OGTT trial**

192 Subjects attended the Human Performance Laboratory at Lancaster University
193 following a two-hour fast and were asked to record and replicate their breakfast meal
194 for each subsequent visit. Upon arrival, an antegrade venous cannula (Vasofix
195 Safety IV Catheter 18G, BBraun, Sheffield, UK) was inserted into the antecubital
196 fossa of the forearm, and a resting blood sample of 1 ml was drawn for blood
197 glucose, lactate, and electrolytes (sodium, potassium, chloride), and a 3 ml sample
198 was taken for insulin using a gold-top serum separator vacutainer (CAT Serum Sep
199 Clot Activator, VACUETTE, Greiner Bio-One, Gloucestershire, UK). Subjects were
200 then seated in a semi-supine position on a medical bed (Plinth 2000, Plinth Medical,
201 Suffolk, UK) and asked to rest quietly for fifteen minutes to allow them to reach a
202 relaxed state, as previously described in research measuring resting metabolic rate
203 (Blannin & Wallis, 2024). To prevent clotting, the cannula was flushed with ~1ml
204 0.9% saline every 15 minutes during each study visit. A flush log was maintained,
205 and on average, 4.6 ± 0.7 ml of saline was used per visit. A small sample was
206 discarded after each flush to ensure the cannula was fully primed with blood before a
207 sample was taken.

208

209 After the 15-minute rest period, subjects consumed 45 g of carbohydrates from
210 either VOOM, MAU or SIS. During the 1-hour OGTT, blood was sampled via an
211 antegrade venous cannula at regular intervals. One ml was collected every five
212 minutes for blood glucose, lactate, and electrolytes. Additionally, three ml of blood
213 was collected every ten minutes for insulin measurement. Substrate utilisation was
214 measured via indirect calorimetry, recording the Respiratory Quotient (RQ).
215 Carbohydrate and fat oxidation were calculated using the Frayn (1983) equations,
216 which are appropriate for resting conditions where steady state assumptions apply:

217

218 Carbohydrate oxidation ($\text{g} \cdot \text{min}^{-1}$) = $4.55 \times \dot{V}\text{CO}_2$ (L/min) - $3.21 \times \dot{V}\text{O}_2$ (L/min)

219

220 Fat oxidation ($\text{g} \cdot \text{min}^{-1}$) = $1.67 \times \dot{V}\text{O}_2$ (L/min) - $1.67 \times \dot{V}\text{CO}_2$ (L/min)

221

222 Carbohydrate oxidation efficiency was calculated as the percentage of the ingested
223 carbohydrate (45 g) that was oxidised, by dividing the total carbohydrate oxidised by
224 45 and multiplying it by 100, as previously described by Hulston et al. (2009).

225

226 **Exercise visits**

227 Subjects consumed a high-carbohydrate control snack bar of 196 kcal, consisting
228 of 64% carbohydrate (27.0 g, of which sugars 11.3 g), 18% fat (7.6 g), and 8%
229 protein (3.6 g), with 2.7 g fibre and 0.36 g salt two hours before attending the Human
230 Performance Lab to mimic pre-training or competition nutrition conditions (Thomas et
231 al., 2016). As with the OGTT, an antegrade venous cannula was inserted into the
232 antecubital fossa of the forearm. Subjects consumed 45 g of carbohydrates from
233 VOOM, MAU or SIS 35 minutes before the start of exercise as the mean time of
234 peak glucose availability identified in the OGTT trial.

235

236 **Repeated sprint protocol**

237 Following a three-minute warm-up cycling at 70 rpm, subjects completed five 15-
238 second maximal sprints against $0.075 \text{ kg} \cdot \text{kg}^{-1}$ body mass interspersed with three
239 minutes of active recovery at 70 rpm against no resistance. In accordance with the
240 ACSM guidelines (Liguori, 2020), the exercise was followed by a supervised active
241 cool-down period, during which subjects continued low intensity cycling. Heart rate

242 was continuously monitored, and subjects remained under observation until their
243 heart rate had returned to within 20% of pre-exercise resting values or until they self-
244 reported readiness to stop. To record gastrointestinal (GI) discomfort before and after
245 exercise, subjects completed a modified version of the Gastrointestinal Symptom
246 Rating Scale (GSRS), shown to have good test-retest reliability in athletes
247 (Wardenaar et al., 2024). Subjects also reported their ratings of perceived exertion
248 (RPE) after the warm-up and after the final sprint using Borg's 6-20 RPE scale (Borg,
249 1982).

250

251 One ml of blood was sampled via an antegrade venous cannula for blood glucose,
252 lactate and electrolytes (sodium, potassium, chloride, and calcium) at baseline, after
253 the warm-up, and then at the end of each sprint and 3-minute recovery period.


254 Substrate utilisation was measured via indirect calorimetry, recording the respiratory
255 exchange ratio (RER), and heart rate was recorded throughout using a chest-worn
256 heart rate monitor (Polar H10, Polar, Kempele, Finland). Carbohydrate oxidation was
257 calculated using the Jeukendrup & Wallis (2005) equations, which are more
258 appropriate for high-intensity exercise, accounting for increased ventilation, lactate
259 production and changes in bicarbonate buffering, while considering protein oxidation
260 negligible:

261

262 Carbohydrate oxidation ($\text{g}\cdot\text{min}^{-1}$) = $4.210 \times \dot{V}\text{CO}_2$ (L/min) - $2.962 \times \dot{V}\text{O}_2$ (L/min)

263

264



265

266

267 Figure 1. Flowchart study design and schematic of the (A) 1-hour Oral Glucose

268 Tolerance Trial (OGTT), and (B) Repeated intermittent sprint intervals.

269

270 **Supplement administration**

271 All supplements were prepared by a laboratory technician in accordance with UK
 272 food hygiene standards and randomised by the laboratory technician using an online
 273 randomisation tool (Research Randomiser: <https://www.randomizer.org>). The
 274 carbohydrate products were labelled A, B and C, with a sealed envelope containing
 275 product details kept securely in a locked cabinet. This envelope was only to be
 276 opened if a subject experienced an adverse reaction, to identify the product involved.
 277 There were no adverse events, so blinding was preserved until analysis was
 278 complete. Following this, the products would be re-randomised and re-blinded to

279 both the subjects and investigators. The study utilised a randomised double-blind
280 crossover design where neither the subjects nor the researchers involved in data
281 collection and analysis knew which supplements were being consumed. The
282 laboratory technician was not involved in analysing the data, maintaining blinding
283 throughout the study. Nutritional information is shown in Table 2.

284

285

286

287

288

289

290

291

292

293

294

295

296

297

298

299

300

301

302

303

304 Table 2. Nutritional information of study supplements

Supplement	Ingredients	Nutritional information (matched for 45 g carbohydrate)
VOOM	Raw Cane Sugar, Glucose Syrup, Water, Dried Fruit (1%), Electrolytes (Tri-sodium Citrate, Pink Himalayan Salt, Potassium Chloride, Magnesium Oxide, Calcium Lactate) (0.3%), Natural Flavouring, B-Vitamins. No artificial sweeteners, thickeners or preservatives	176 kcal, 45 g carbohydrates, 41 g of which sugar, 0 g fat, 0 g protein, trace salt, 1 mg B-Vitamins, 120 mg electrolytes
MAU	Water, glucose, fructose, gelling agent: calcium carbonate, gelling agent: gluconic acid, gelling agent: sodium alginate	180 kcal, 45 g carbohydrates, 45 g of which sugars, 0 g fat, 0 g protein, 90 mg salt
SIS	Water, Maltodextrin (from Maize) (33%), Gelling Agents (Gellan Gum, Xanthan Gum), Natural Flavouring, Acidity Regulators (Citric Acid, Sodium Citrate), Preservatives (Sodium Benzoate, Potassium Sorbate), Sweetener (Acesulfame K), Sodium Chloride, Antioxidant (Ascorbic Acid)	178 kcal, 45 g carbohydrates, 1.23 g of which sugars, 0 g fat, 0 g protein, 20 mg salt

305

306 **Blood analysis**

307 Blood glucose and lactate were analysed immediately using a bench-top blood
 308 analyser (Biosen C-Line GP+, EKF, Barleben, Germany). For insulin, the 3 ml
 309 vacutainer was inverted several times and left to clot at room temperature for 15
 310 minutes before being centrifuged at 4°C, 1800 RCF, for 10 minutes. The supernatant

311 was then transferred to a microfuge tube and stored at -20°C during the study day
312 before moving to -80°C after the study visit for analysis at a future date.

313

314 **Insulin analysis**

315 Insulin was measured using an enzyme-linked immunosorbent assay (ELISA)
316 (Human Insulin ELISA Kit, CrystalChem, Illinois, USA). Samples were prepared and
317 analysed, and absorbance was read at both 450 nanometres (nm) and 630 nm
318 before subtracting the 630 nm absorbance readings from the 450 nm absorbance
319 readings, following the manufacturer's protocol. Insulin concentrations are presented
320 as micro-units per millilitre (µU/mL).

321

322 Missing insulin values (VOOM = 7.8%, MAU = 8.6%, SIS = 6.3%) were imputed
323 using a Monte Carlo methodology to minimise bias from incomplete observations
324 (Schafer, 1997; Dong et al., 2013; Austin & van Buuren, 2022).

325

326 To enable temporal comparisons between glucose and insulin, values were
327 normalised to a 0 -100% scale based on the range of each data set (where 0%
328 represented the lowest value and 100% the highest value), previously described by
329 Atherton et al. (2010). Normalisation reflected each subject's percentage change
330 from baseline at 10-minute intervals during the OGTT, using the following equation:

331

332
$$([\text{Current Value} - \text{Baseline Value}]/[\text{Maximum Value} - \text{Minimum Value}]) \times 100$$

333

334 Following normalisation, the relative changes in glucose and insulin over time were
335 compared to examine the temporal dynamics of both variables across the 1-hour
336 OGTT.

337

338 **Electrolyte analysis**

339 The supernatant was analysed for electrolyte content using an electrolyte analyser (i-
340 smart 30 PRO, Woodley Laboratory Diagnostics, Bolton, United Kingdom). Ten
341 microlitres were inserted into the tip of the electrolyte reader and analysed for
342 sodium, potassium, chloride, and calcium.

343

344 **Statistical analysis**

345 Data normality were assessed using Shapiro-Wilk tests. Results are reported as
346 mean \pm SD unless stated otherwise. Normally distributed time-series data were
347 analysed using two-way repeated measures ANOVA with product and time as within-
348 subject factors. Significant main or interaction effects were followed up with a Tukey
349 multiple comparison test. Non-parametric data were analysed using a Friedman test,
350 with Dunn's post-hoc tests for significant effects. Data analysis and figure
351 preparation were conducted using GraphPad Prism 10.4.1 (GraphPad Software, San
352 Diego, CA, USA). Statistical significance was set at $p < 0.05$.

353

354 **Results**

355

356 **Resting OGTT**


357 **Blood glucose and insulin responses to OGTT**

358 A significant main effect of time was found for both glucose and insulin ($p < 0.001$),
359 with no significant differences between products or interaction between time and
360 product ($p > 0.05$). The area under the curve for glucose was similar between
361 products (total area \pm standard error) (VOOM 314.3 ± 12.45 , MAU 317.2 ± 12.10 ,
362 SIS 316.50 ± 12.04). Mean peak glucose concentration (VOOM 6.59 ± 1.18 , MAU
363 6.20 ± 1.14 mmol/L, SIS 6.42 ± 1.15 mmol/L) and time to glucose peak (VOOM
364 31.25 ± 13.96 min, MAU 39.06 ± 12.28 min, SIS 33.13 ± 11.09 min) showed no
365 statistical significance between products, nor any interaction effect ($p > 0.05$),
366 reflecting comparable glucose metabolism across the OGTT.

367

368 VOOM elicited a greater area under the curve for insulin (total area \pm standard error)
369 (185.8 ± 43.77) than MAU (156.7 ± 44.76) and SIS (121.4 ± 29.35), indicating a
370 greater or more prolonged insulin response when consuming VOOM.

371



372

373 Figure 2. (A) Blood glucose and (B) insulin concentrations were similar between
 374 VOOM, MAU and SIS in a modified 1-hour OGTT ($p > 0.05$). Normalised (data span
 375 = 100%) mean \pm SD comparisons between insulin and glucose in response to 45 g
 376 carbohydrate showed no differences between insulin and glucose for (C) VOOM, (D)
 377 MAU, and (E) SIS, ($p > 0.05$).

378

379 Following normalisation, the relative changes in glucose and insulin over time were
380 compared to examine the temporal pattern of glucose and insulin throughout the
381 study period. Both variables were presented as percentage changes from baseline
382 (0%) and plotted for each participant every 10 minutes across the 1-hour OGTT. This
383 normalisation approach enabled direct comparison of glucose and insulin dynamics
384 independent of individual baseline values. A two-way repeated measures ANOVA
385 revealed a main effect of time ($p < 0.0001$) but no significant product or interaction
386 effect between glucose and insulin concentrations ($p > 0.05$).

387

388 **VOOM enhances carbohydrate oxidation**




389 A one-way repeated measures ANOVA revealed total carbohydrate oxidation
390 significantly differed between products ($p = 0.01$). Tukey multiple comparisons
391 revealed that VOOM had significantly greater total carbohydrate oxidation across the
392 1h OGTT than SIS (VOOM 24.63 ± 7.38 g, SIS 17.77 ± 8.61 g, $p = 0.03$, Figure 3A),
393 despite matched carbohydrate provision. No differences were observed between
394 MAU and VOOM, or MAU and SIS (MAU 20.11 ± 6.41 g, $p > 0.05$).

395

396 A one-way repeated measures ANOVA revealed carbohydrate oxidation efficiency
397 significantly differed between products ($p = 0.01$). Tukey multiple comparisons test
398 showed that VOOM had a significantly greater carbohydrate oxidation efficiency than
399 SIS (VOOM 54.73 ± 16.4 %, SIS 39.5 ± 19.15 %, $p = 0.03$, Figure 3B). No differences
400 were seen between MAU and VOOM or MAU and SIS (MAU 44.68 ± 14.25 %, $p >$
401 0.05).

402

403 In keeping with the carbohydrate oxidation data, a one-way repeated measures
404 ANOVA showed total fat oxidation significantly differed between products ($p = 0.01$).
405 Indeed, total fat oxidation was suppressed to a greater extent in VOOM than SIS
406 (SIS 9.45 ± 3.41 g, VOOM 7.37 ± 2.29 g, $p = 0.006$, Figure 3C). No differences were
407 observed between MAU and VOOM or MAU and SIS (MAU 8.46 ± 3.41 g, $p > 0.05$).
408






410 Figure 3. (A) Consuming VOOM resulted in a significant increase in total
411 carbohydrate oxidation compared to SIS in a modified 1-hour OGTT ($p = 0.03$). (B)
412 Carbohydrate oxidation efficiency was significantly greater in VOOM than SIS ($p =$
413 0.03). (C) Total fat oxidation was suppressed to a greater extent for VOOM than SIS
414 ($p = 0.006$) during the 1-hour modified OGTT. * $p < 0.05$; ** $p < 0.01$.

415

416 A two-way repeated measures ANOVA revealed a significant main effect for both
417 time ($p < 0.0001$) and product ($p = 0.04$) on carbohydrate oxidation per minute, but
418 no interaction effect was present ($p > 0.05$), Figure. 4A. VOOM elicited a greater
419 mean carbohydrate oxidation rate ($0.27 \pm 0.05 \text{ g}\cdot\text{min}^{-1}$) than MAU (0.21 ± 0.05
420 $\text{g}\cdot\text{min}^{-1}$) and SIS ($0.19 \pm 0.06 \text{ g}\cdot\text{min}^{-1}$). Tukey multiple comparisons showed that at
421 15 minutes, VOOM had a significantly greater carbohydrate oxidation rate per minute
422 than SIS (VOOM $0.25 \pm 0.15 \text{ g}\cdot\text{min}^{-1}$; SIS $0.12 \pm 0.07 \text{ g}\cdot\text{min}^{-1}$, $p = 0.019$). At 40
423 minutes, VOOM had a significantly greater carbohydrate oxidation rate per minute
424 than both MAU (VOOM $0.32 \pm 0.09 \text{ g}\cdot\text{min}^{-1}$; MAU $0.23 \pm 0.10 \text{ g}\cdot\text{min}^{-1}$, $p = 0.03$) and
425 SIS (VOOM $0.32 \pm 0.09 \text{ g}\cdot\text{min}^{-1}$; $0.23 \pm 0.11 \text{ g}\cdot\text{min}^{-1}$, $p = 0.04$). Similarly, at 50
426 minutes, VOOM's carbohydrate oxidation rate per minute was significantly greater
427 than MAU (VOOM $0.33 \pm 0.17 \text{ g}\cdot\text{min}^{-1}$; MAU $0.19 \pm 0.08 \text{ g}\cdot\text{min}^{-1}$, $p = 0.019$) and SIS
428 (VOOM $0.33 \pm 0.17 \text{ g}\cdot\text{min}^{-1}$; SIS $0.20 \pm 0.07 \text{ g}\cdot\text{min}^{-1}$, $p = 0.03$).

429



431 Figure 4. (A) VOOM elicited significantly greater CHO (carbohydrate) oxidation than
432 SIS at 15 mins ($p = 0.019$) and greater than MAU ($p = 0.03$) and SIS ($p = 0.04$) at 40
433 mins and greater than MAU ($p = 0.019$) and SIS ($p = 0.03$) at 50 mins. (B) A higher
434 RQ for VOOM than MAU and SIS, indicating increased carbohydrate use. * $p < 0.05$
435 for VOOM vs SIS. † $p < 0.05$ for VOOM vs MAU. (C) Blood lactate was significantly
436 greater for VOOM than SIS at 35 minutes ($p = 0.01$). * $p < 0.05$.

437

438 A Friedman test was conducted on the non-parametric RQ data, revealing significant
439 differences among products, $X^2 (38) = 187.8$, $p < 0.0001$, as shown in Figure 4B.
440 above. Dunn's multiple comparisons revealed no significant differences between
441 products. Mean ranks were as follows: VOOM (24), MAU (18), and SIS (16). Raw
442 data means; VOOM (0.86 ± 0.06), MAU (0.84 ± 0.07), and SIS (0.83 ± 0.07).

443

444 A Friedman test revealed a significant difference in lactate concentration between
445 the products ($X^2 (41) = 253$, $p < 0.001$). VOOM had a greater mean rank for lactate
446 concentration (26) than MAU (20) and SIS (17). This was consistent with the raw
447 mean data (VOOM 1.08 ± 0.42 mmol/L, MAU 0.91 ± 0.30 mmol/L, SIS 0.81 ± 0.31
448 mmol/L). Dunn's multiple comparisons revealed a significantly greater lactate
449 concentration in VOOM than in SIS at 35 minutes (VOOM mean rank = 29, raw data
450 mean = 1.17 ± 0.49 mmol/L, SIS mean rank = 14, raw data mean = 0.77 ± 0.28
451 mmol/L, $p = 0.01$, Figure 4C).

452

453 **No differences between electrolytes**


454 There were no significant differences in the electrolyte content measured (sodium,
455 potassium and chloride), with levels remaining similar throughout ($p > 0.05$).

456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474

Exercise study

Sex differences in performance metrics – warrant further investigation

A two-way repeated measures ANOVA revealed a significant effect of sex on mean peak power ($p < 0.0001$). Tukey multiple comparisons showed significant differences between males and females for VOOM (males 861.4 ± 97.45 watts; females 612 ± 94.47 watts, $p = 0.01$), MAU (males 826.8 ± 93.79 watts; females 601.9 ± 94.30 watts $p = 0.02$) and SIS (males 856.7 ± 101.3 watts; females 599.5 ± 104.9 watts, $p = 0.01$), Figure 4A. A similar effect was found for mean power ($p < 0.0001$), with significant differences for VOOM (males 684.7 ± 65.96 watts; females 501.4 ± 53.97 watts, $p = 0.01$), MAU (males 668.4 ± 66.83 watts; females 518.9 ± 51.28 watts $p = 0.04$) and SIS (males 691.5 ± 67.97 watts; females 487.3 ± 63.58 watts, $p = 0.006$), Figure 4B. A significant effect of sex was also observed for total work ($p < 0.0001$), with males performing significantly more work for VOOM (males 10131 ± 982.4 kJ; females 7365 ± 838.4 kJ, $p = 0.01$), MAU (males 10047 ± 1096 kJ; females 7559 ± 708.2 kJ, $p = 0.02$), and SIS (males 10231 ± 1096 kJ; females $(7208 \pm 927.2$ kJ, $p = 0.007$), Figure 4C. No significant sex effect was found for the fatigue index ($p = 0.20$).



475

476 Figure 5. During the repeated sprints, males produced significantly greater readings

477 than females for (A) Peak power, (B) Mean power, and (C) Total work when

478 averaged across all five repeated sprints. (D) No significant effect of sex was shown

479 for the Fatigue index ($p > 0.05$). * $p < 0.05$; ** $p < 0.01$. kJ = kilojoules.

480

481 Performance metrics were comparable between products




482 A two-way repeated measures ANOVA for peak power per sprint revealed a

483 significant effect of time ($p = 0.01$) but no product effect (VOOM 736.7 ± 10.51 watts;

484 MAU 716.4 ± 21.2 watts; SIS 728.5 ± 17.08 watts, $p = 0.90$) or time x product

485 interaction were found ($p = 0.90$). A similar trend was observed for mean power per

486 sprint, where a significant effect for time was found ($p = 0.0002$), but no difference
487 was detected between products (VOOM 593.1 ± 19.17 watts; MAU 593.1 ± 19.63
488 watts; SIS 589 ± 16.41 watts, $p = 0.9$) or for the interaction effect ($p = 0.80$). Total
489 work per sprint was also influenced by time ($p < 0.0001$) but not product (VOOM
490 8766 ± 290 kJ; MAU 8701 ± 251 kJ; SIS 8720 ± 263 kJ, $p = 0.90$) or time x product
491 interaction ($p = 0.90$), as depicted in Figure 6. No significant effect was found for the
492 fatigue index (VOOM $38.6 \pm 8.1\%$; MAU $38.3 \pm 10.0\%$; SIS $36.3 \pm 9.6\%$, $p = 0.20$).
493



495 Figure 6. Comparable results in (A) Peak power, (B) Mean power, and (C) Total work
496 per sprint between VOOM, MAU and SIS. kJ = kilojoules

497

498 **Similar substrate utilisation and electrolyte responses across carbohydrate**
499 **products**

500 A significant main effect of time was shown for glucose ($p < 0.0001$) and lactate ($p <$
501 0.0001), but no effect of product or time x product interaction were present ($p >$
502 0.05). No significant main or interaction effects were shown for carbohydrate
503 oxidation nor carbohydrate oxidation efficiency ($p > 0.05$), indicating similar
504 exogenous carbohydrate utilisation across products. RER had a significant main
505 effect of time ($p < 0.0001$), but not product or time x product interaction ($p > 0.05$),
506 further supporting comparable substrate utilisation during repeated sprints (see Table
507 S1). A main effect of time was seen for potassium ($p = 0.001$) and chloride ($p =$
508 0.02), but no main effect of product or time x product interaction was shown. No
509 main or interaction effects were shown for sodium or calcium ($p > 0.05$).

510

511 **Minimal gastrointestinal discomfort and comparable perceptual responses**
512 **across carbohydrate products**

513 There were no significant main or interaction effects ($p > 0.05$) in GI discomfort, with
514 subjects reporting minimal GI discomfort throughout, demonstrating comparable
515 tolerability with both the volume and compositions of each carbohydrate product (see
516 Table S1). No significant main or interaction effects were seen for heart rate or RPE
517 ($p > 0.05$).

518

519 **Discussion**

520 This research found that the VOOM glucose-fructose energy bar resulted in a higher
521 carbohydrate oxidation rate in a resting state compared to the MAU hydrogel
522 (fructose-glucose) and SIS gel (maltodextrin-based). Higher carbohydrate oxidation
523 is beneficial as it supports adenosine triphosphate (ATP) production, helping to fuel
524 muscle contractions and delay fatigue (González-Marengo et al., 2024). This
525 increased carbohydrate oxidation is likely what led to the significantly greater lactate
526 concentration in VOOM compared to SIS, as the greater breakdown of
527 carbohydrates through aerobic glycolysis may have led to more pyruvate being fully
528 oxidised, resulting in excess pyruvate being converted to lactate (Hargreaves &
529 Spreit, 2020). However, the significant differences in substrate oxidation between
530 products seen in the OGTT did not translate into significant differences in exercise
531 performance nor changes in glycaemia during repeated sprint intervals.

532

533 Differences in the carbohydrate formulations and compositions likely influenced
534 these findings. The glucose-fructose mix used in likely increased carbohydrate
535 oxidation due to its immediate availability of free glucose combined with fructose,
536 utilising both SGLT1 and GLUT5 transporters (Jentjens et al., 2004; Jeukendrup,
537 2010), allowing for rapid oxidation and energy availability. In contrast, SIS relies on
538 maltodextrin, which must be broken down to glucose before absorption (Hofman et
539 al., 2016), potentially causing a slight delay in oxidation. MAU utilises a hydrogel
540 formula comprised of three-dimensional hydrophilic polymers containing sodium
541 alginate and pectin, which aid the absorption of multiple transportable carbohydrates
542 by delivering them gradually at a pH level that is biocompatible to the stomach and
543 intestine (King et al., 2020; Rowe et al., 2022). This may slow the release of sugars
544 into the bloodstream and result in reduced carbohydrate oxidation compared with

545 VOOM. These differences highlight how formulation and carbohydrate type influence
546 oxidation rate and energy availability.

547

548 Although there were metabolic differences during the OGTT, including increased
549 carbohydrate oxidation with VOOM, these did not translate to improved performance
550 during repeated sprint cycling. This may reflect the nature of energy provision during
551 short, high-intensity efforts, which relies predominantly on phosphocreatine and
552 intramuscular glycogen, rather than circulating glucose, with previous research
553 demonstrating carbohydrate supplementation has little effect on glycogen depletion
554 during short-duration, high-intensity intermittent exercise, even when blood glucose
555 is elevated (Vigh-Larsen et al., 2024).

556

557 During the recovery periods between sprints, fat oxidation likely contributed more to
558 energy provision; however, carbohydrate supplementation may have helped to
559 maintain glycaemia, potentially delaying the onset of fatigue associated with
560 hypoglycaemia (Cao et al., 2025; Prins et al., 2025). In this aspect, the present study
561 showed similar reductions in performance over the five sprints with all three
562 supplements and no differences in RPE, suggesting that no one product was
563 superior in maintaining performance or reducing the perception of fatigue. Thus, the
564 exogenous effects of carbohydrate supplementation may be more relevant to
565 prolonged or glycogen-depleting exercise, where maintaining glycaemia or delaying
566 glycogen depletion plays a more critical role (Kuipers et al. 1987; and Podlogar et al.
567 2023; Wallis et al. 2008).

568

569 None of the subjects reported significant GI discomfort during repeated sprints after
570 consuming any of the three carbohydrate supplements (VOOM, MAU, SIS), each
571 providing 45 g of carbohydrate – a valuable finding given concerns around exercise-
572 induced GI symptoms (Gaskell et al., 2023; Ribichini et al., 2023). While minimal
573 discomfort has been reported with hydrogel or gel-based formulations (Hearris et al.,
574 2022; Rowe et al., 2022), the absence of symptoms with the solid VOOM bar is
575 notable, as earlier research linked solid forms to greater GI discomfort (Guillochon &
576 Rowlands, 2017; Pfeiffer et al., 2010). However, more recent evidence suggests
577 improved GI tolerance with solid supplements (Hearris et al., 2022). Our findings
578 support this, indicating that well-formulated solid carbohydrates can be comfortable
579 consumed even during high-intensity exercise, reassuring athletes who may prefer
580 solid options for practical or palatability reasons.

581

582 **Limitations**

583 Full blinding of subjects was not possible due to the differing physical forms of the
584 supplements, with VOOM provided as a bar, MAU as a hydrogel, and SIS as a gel,
585 making them distinguishable upon consumption. However, subjects were unaware of
586 product names physical forms prior to consumption, limiting the risk of bias. The
587 study also used antegrade rather than retrograde venous cannulation. Antegrade
588 cannulation is a less invasive method with minimal impact on metabolite
589 measurement accuracy (Wrench et al., 2024).

590

591 A further limitation is the lack of direct measurement of muscle glycogen, which
592 would have provided a clearer understanding of glycogen utilisation and recovery in
593 response to carbohydrate supplementation. Future studies incorporating muscle

594 biopsies could enhance the confidence and precision of interpretations relating to
595 substrate utilisation.

596

597 **Conclusion**

598 The findings of this study show that the VOOM glucose-fructose bar elicits greater
599 carbohydrate oxidation at rest compared to MAU and SIS, providing athletes with an
600 effective alternative for carbohydrate supplementation. However, these metabolic
601 differences did not enhance repeated sprint cycling performance – an exercise
602 intensity less dependent on sustained carbohydrate availability – suggesting such
603 benefits may be more applicable to conditions where blood glucose has a greater
604 effect on performance, such as during prolonged or glycogen-depleting exercise.

605

606 **Competing interests**

607 ED was supported by Omega EFA Ltd, trading as Team Nutrition, to complete a
608 Masters by Research.

609

610 **Funding statement**

611 This research was funded by Omega EFA Ltd, trading as Team Nutrition. The funder
612 had no role in the study design, trial execution, data analyses, interpretation of the
613 data, or decision to submit results.

614

615 **Data availability statement**

616 Data generated or analysed during this study are provided in full within the published
617 article.

618

619 **Supplementary table**

620 Table S1. Physiological and metabolic responses under VOOM, MAU and SIS

	VOOM	MAU	SIS
Glucose (mmol/L)	4.50 ± 0.53	4.77 ± 0.42	5.08 ± 0.52
Lactate (mmol/L)	5.16 ± 3.09	5.09 ± 2.88	4.95 ± 2.92
Potassium (mmol/L)	4.52 ± 0.25	4.69 ± 0.32	4.51 ± 0.28
Chloride (mmol/L)	106.6 ± 0.87	106.3 ± 0.46	106 ± 0.66
Sodium (mmol/L)	139.9 ± 1.77	139.7 ± 1.09	140.2 ± 1.6
Calcium (mmol/L)	1.18 ± 0.03	1.21 ± 0.01	1.19 ± 0.02
RER	1.08 ± 0.08	1.04 ± 0.06	1.05 ± 0.07
Heart rate (bpm)	126 ± 21	129 ± 20	131 ± 21
CHO oxidation (g·min ⁻¹)	2.4 ± 0.7	2.1 ± 0.5	2.3 ± 0.7
CHO oxidation efficiency (%)	47.3 ± 12.0	51.5 ± 15.5	53.2 ± 12.9
Δ GI	0.7 ± 1.06	0.6 ± 1.08	0.3 ± 0.66
Δ RPE	9.1 ± 1.8	8.2 ± 2.5	9.5 ± 1.4

621 CHO = Carbohydrate. Δ RPE = Change in the rating of perceived exertion. Δ GI Discomfort = Change
 622 in gastrointestinal discomfort score.

623

624 **References**

625

626 **Atherton P.J., Etheridge T., Watt P.W., Wilkinson D., Selby A., Rankin D., Smith**
 627 **K. and Rennie M.J. 2010. Muscle full effect after oral protein: time-dependent**
 628 **concordance and discordance between human muscle protein synthesis and**
 629 **mTORC1 signaling. Am.J.Clin.Nutr. 92(5): 1080–1088.**

630

631 **Austin P.C. and van Buuren S. 2022. The effect of high prevalence of missing**
632 **data on estimation of the coefficients of a logistic regression model when**
633 **using multiple imputation. 22(1): 196.**
634

635 **Baker L.B., Rollo I., Stein K.W. and Jeukendrup A.E. 2015. Acute effects of**
636 **carbohydrate supplementation on intermittent sports performance. 7(7): 5733–**
637 **5763.**
638

639 **Blannin A.K. and Wallis G.A. 2024. Effects of overnight-fasted versus fed-state**
640 **exercise on the components of energy balance and interstitial glucose across**
641 **four days in healthy adults. 203107716.**
642

643 **Borg G.A. 1982. Psychophysical bases of perceived exertion. Med.Sci.Sports**
644 **Exerc. 14(5): 377–381.**
645

646 **Cao W., He Y., Fu R., Chen Y., Yu J. and He Z. 2025. A Review of Carbohydrate**
647 **Supplementation Approaches and Strategies for Optimizing Performance in**
648 **Elite Long-Distance Endurance. 17(5): 918.**
649

650 **Ciarambino T., Crispino P., Guarisco G. and Giordano M. 2023. Gender**
651 **differences in insulin resistance: new knowledge and perspectives.**
652 **Curr.Issues Mol.Biol. 45(10): 7845–7861.**
653

654 **Dong Y. and Peng C.J. 2013. Principled missing data methods for researchers.**
655 **2 1–17.**

656

657 **Frayn K.N. 1983. Calculation of substrate oxidation rates in vivo from gaseous**
658 **exchange. J.Appl.Physiol. 55(2): 628–634.**

659

660 **Gaffney C.J., Cunnington J., Rattley K., Wrench E., Dyche C. and Bampouras**
661 **T.M. 2022. Weighted vests in CrossFit increase physiological stress during**
662 **walking and running without changes in spatiotemporal gait parameters. 65(1):**
663 **147–158.**

664

665 **Gaskell S.K., Burgell R., Wiklendt L., Dinning P.G. and Costa R.J. 2023. Impact**
666 **of exercise duration on gastrointestinal function and symptoms.**
667 **J.Appl.Physiol. 134(1): 160–171.**

668

669 **González-Marenco R., Estrada-Sánchez I.A., Medina-Escobedo M., Chim-Aké R.**
670 **and Lugo R. 2024. The effect of Oral adenosine triphosphate (ATP)**
671 **supplementation on anaerobic exercise in healthy resistance-trained**
672 **individuals: a systematic review and Meta-analysis. 12(3): 82.**

673

674 **Gromova L.V., Fetisov S.O. and Gruzdkov A.A. 2021. Mechanisms of glucose**
675 **absorption in the small intestine in health and metabolic diseases and their**
676 **role in appetite regulation. 13(7): 2474.**

677

678 **Guillochon M. and Rowlands D.S. 2017. Solid, gel, and liquid carbohydrate**
679 **format effects on gut comfort and performance. Int.J.Sport**
680 **Nutr.Exerc.Metab. 27(3): 247–254.**

681

682 **Hargreaves M. and Spriet L.L. 2020. Skeletal muscle energy metabolism during**
683 **exercise. 2(9): 817–828.**

684

685 **Hearris M.A., Pugh J.N., Langan-Evans C., Mann S.J., Burke L., Stellingwerff T.,**
686 **Gonzalez J.T. and Morton J.P. 2022. 13C-glucose-fructose labeling reveals**
687 **comparable exogenous CHO oxidation during exercise when consuming 120**
688 **g/h in fluid, gel, jelly chew, or coingestion. J.Appl.Physiol. 132(6): 1394–1406.**

689

690 **Hofman D.L., Van Buul V.J. and Brouns F.J. 2016. Nutrition, health, and**
691 **regulatory aspects of digestible maltodextrins. Crit.Rev.Food Sci.Nutr. 56(12):**
692 **2091–2100.**

693

694 **Hulston C.J., Wallis G.A. and Jeukendrup A.E. 2009. Exogenous CHO oxidation**
695 **with glucose plus fructose intake during exercise. Med.Sci.Sports Exerc. 41(2):**
696 **357–363.**

697

698 **Ismardi I., Rahman D., Rifki M.S., Welis W., Okilanda A. and Ockta Y. 2024. The**
699 **Importance of Carbohydrate Intake for Maintaining Glycogen Stores and**
700 **Physical Performance during Prolonged Exercise: A Literature Review.**
701 **10(SpecialIssue): 83–89.**

702

703 **Jentjens R.L., Moseley L., Waring R.H., Harding L.K. and Jeukendrup A.E. 2004.**
704 **Oxidation of combined ingestion of glucose and fructose during exercise.**
705 **J.Appl.Physiol.**

706

707 **Jeukendrup A.E. and Wallis G.A. 2005. Measurement of substrate oxidation**
708 **during exercise by means of gas exchange measurements. Int.J.Sports**
709 **Med. 26(S 1): S28–S37.**

710

711 **Jeukendrup A. 2014. A step towards personalized sports nutrition:**
712 **carbohydrate intake during exercise. 44(Suppl 1): 25–33.**

713

714 **Jeukendrup A.E. 2010. Carbohydrate and exercise performance: the role of**
715 **multiple transportable carbohydrates. 13(4): 452–457.**

716

717 **Jeukendrup A.E. and Jentjens R. 2000. Oxidation of carbohydrate feedings**
718 **during prolonged exercise: current thoughts, guidelines and directions for**
719 **future research. 29 407–424.**

720

721 **Kazemi A., Racil G., Ahmadi Hekmatikar A.H., Behnam Moghadam M., Karami P.**
722 **and Henselmans M. 2023. Improved physical performance of elite soccer**
723 **players based on GPS results after 4 days of carbohydrate loading followed by**
724 **3 days of low carbohydrate diet. 20(1): 2258837.**

725

726 **King A.J., Rowe J.T. and Burke L.M. 2020. Carbohydrate hydrogel products do**
727 **not improve performance or gastrointestinal distress during moderate-**
728 **intensity endurance exercise. Int.J.Sport Nutr.Exerc.Metab. 30(5): 305–314.**

729

730 **Krings B.M., Peterson T.J., Shepherd B.D., McAllister M.J. and Smith J.W. 2017.**
731 **Effects of carbohydrate ingestion and carbohydrate mouth rinse on repeat**
732 **sprint performance. *Int.J.Sport Nutr.Exerc.Metab.* 27(3): 204–212.**
733

734 **Kuipers H., Keizer H.A., Brouns F. and Saris W. 1987. Carbohydrate feeding**
735 **and glycogen synthesis during exercise in man. 410 652–656.**
736

737 **McKay A.K., Stellingwerff T., Smith E.S., Martin D.T., Mujika I., Goosey-Tolfrey**
738 **V.L., Sheppard J. and Burke L.M. 2021. Defining training and performance**
739 **caliber: a participant classification framework. 17(2): 317–331.**
740

741 **Pfeiffer B., Stellingwerff T., Zaltas E. and Jeukendrup A.E. 2010. Oxidation of**
742 **solid versus liquid CHO sources during exercise. *Med.Sci.Sports Exerc.* 42(11):**
743 **2030–2037.**
744

745 **Podlogar T., Bokal Š, Cirnski S. and Wallis G.A. 2022. Increased exogenous but**
746 **unaltered endogenous carbohydrate oxidation with combined fructose-**
747 **maltodextrin ingested at 120 g h⁻¹ versus 90 g h⁻¹ at different ratios.**
748 ***Eur.J.Appl.Physiol.* 122(11): 2393–2401.**
749

750 **Podlogar T., Shad B.J., Seabright A.P., Odell O.J., Lord S.O., Civil R., Salgueiro**
751 **R.B., Shepherd E.L., Lalor P.F. and Elhassan Y.S. 2023. Postexercise muscle**
752 **glycogen synthesis with glucose, galactose, and combined galactose-glucose**
753 **ingestion.**
754

755 **Podlogar T. and Wallis G.A. 2022. New horizons in carbohydrate research and**
756 **application for endurance athletes. 52(Suppl 1): 5–23.**
757

758 **Prins P.J., Noakes T.D., Buga A., Gerhart H.D., Cobb B.M., D’Agostino D.P.,**
759 **Volek J.S., Buxton J.D., Heckman K. and Plank E. 2025. Carbohydrate Ingestion**
760 **Eliminates Hypoglycemia & Improves Endurance Exercise Performance in**
761 **Triathletes Adapted to Very Low & High Carbohydrate Isocaloric Diets.**
762

763 **Rauch C.E., McCubbin A.J., Gaskell S.K. and Costa R.J. 2022. Feeding**
764 **tolerance, glucose availability, and whole-body total carbohydrate and fat**
765 **oxidation in male endurance and ultra-endurance runners in response to**
766 **prolonged exercise, consuming a habitual mixed macronutrient diet and**
767 **carbohydrate feeding during exercise. 12 773054.**
768

769 **Ribichini E., Scalese G., Cesarini A., Mocchi C., Pallotta N., Severi C. and**
770 **Corazziari E.S. 2023. Exercise-induced gastrointestinal symptoms in**
771 **endurance sports: A review of pathophysiology, symptoms, and nutritional**
772 **management. 2(3): 289–307.**
773

774 **Rodriguez-Giustiniani P., Rollo I., Witard O.C. and Galloway S.D. 2019.**
775 **Ingesting a 12% carbohydrate-electrolyte beverage before each half of a**
776 **soccer match simulation facilitates retention of passing performance and**
777 **improves high-intensity running capacity in academy players. Int.J.Sport**
778 **Nutr.Exerc.Metab. 29(4): 397–405.**
779

780 **Rollo I., Gonzalez J.T., Fuchs C.J., van Loon L.J. and Williams C. 2020. Primary,**
781 **secondary, and tertiary effects of carbohydrate ingestion during exercise.**
782 **50 1863–1871.**

783

784 **Rosset R., Egli L. and Lecoultre V. 2017. Glucose–fructose ingestion and**
785 **exercise performance: The gastrointestinal tract and beyond. 17(7): 874–884.**

786

787 **Rowe J.T., King R.F., King A.J., Morrison D.J., Preston T., Wilson O.J. and**
788 **O'hara J.P. 2022. Glucose and fructose hydrogel enhances running**
789 **performance, exogenous carbohydrate oxidation, and gastrointestinal**
790 **tolerance. Med.Sci.Sports Exerc. 54(1): 129–140.**

791

792 **Saunders M.J., Luden N.D. and Herrick J.E. 2007. Consumption of an oral**
793 **carbohydrate-protein gel improves cycling endurance and prevents**
794 **postexercise muscle damage. 21(3): 678–684.**

795

796 **Schafer J.L. 1997. Analysis of incomplete multivariate data. CRC press.**

797

798 **Smith E.S., Weakley J., McKay A.K., McCormick R., Tee N., Kuikman M.A.,**
799 **Harris R., Minahan C., Buxton S. and Skinner J. 2024. Minimal influence of the**
800 **menstrual cycle or hormonal contraceptives on performance in female rugby**
801 **league athletes. 24(8): 1067–1078.**

802

803 **Thomas D.T., Erdman K.A. and Burke L.M. 2016. Position of the Academy of**
804 **Nutrition and Dietetics, Dietitians of Canada, and the American College of**
805 **Sports Medicine: nutrition and athletic performance. 116(3): 501–528.**

806

807 **Tucker J.A., McCarthy S.F., Bornath D.P., Khoja J.S. and Hazell T.J. 2025. The**
808 **effect of the menstrual cycle on energy intake: A systematic review and meta-**
809 **analysis. Nutr.Rev. 83(3): e866–e876.**

810

811 **Vigh-Larsen J.F., Kruse D.Z., Moseholt M.B., Hansen L.G., Christensen A.L.,**
812 **Bæk A., Andersen O.E., Mohr M. and Overgaard K. 2024. No Effects of**
813 **Carbohydrate Ingestion on Muscle Metabolism or Performance During Short-**
814 **Duration High-Intensity Intermittent Exercise. Scand.J.Med.Sci.Sports . 34(9):**
815 **e14731.**

816

817 **Wallis G.A., Hulston C.J., Mann C.H., Roper H.P., Tipton K.D. and Jeukendrup**
818 **A.E. 2008. Postexercise muscle glycogen synthesis with combined glucose**
819 **and fructose ingestion. 40(10): 1789–1794.**

820

821 **Wallis G.A., Rowlands D.S., Shaw C., Jentjens R.L. and Jeukendrup A.E. 2005.**
822 **Oxidation of combined ingestion of maltodextrins and fructose during**
823 **exercise. Med.Sci.Sports Exerc. 37(3): 426–432.**

824

825 **Wardenaar F.C., Chan Y., Clear A.M., Schott K., Mohr A.E., Ortega-Santos C.P.,**
826 **Seltzer R.G. and Pugh J. 2024. The Gastrointestinal Symptom Rating Scale has**

827 **a Good Test–Retest Reliability in Well-Trained Athletes With and Without**
828 **Previously Self-Identified Gastrointestinal Complaints 1–12.**

829

830 **World Medical Association. 2025. World Medical Association Declaration of**
831 **Helsinki: Ethical Principles for Medical Research Involving Human**
832 **Participants. 331(1): 71–74.**

833

834 **Wrench E., Subar D.A., Bampouras T.M., Lauder R.M. and Gaffney C.J. 2024.**
835 **Myths and methodologies: Assessing glycaemic control and associated**
836 **regulatory mechanisms in human physiology research. Exp.Physiol. 109(9):**
837 **1461–1477.**

838

839